Skip to main content

Table 5 Hospitalization days in different treatment groups or in patients with or without Arbidol based on gender, age and maximum body temperature

From: Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

Feature

Without Arbidol (n = 49)

With Arbidol (n = 72)

p value

OR (95% CI)

Hospital day [M (IQR)]

18 (16, 20)

17 (14, 21)

0.25

 
 

Control (n = 21)

Other antiviral drugs (n = 28)

Arbidol only (n = 48)

Arbidol + other antiviral drugs (n = 24)

Hospital day [M (IQR)]

19 (17, 21)

18 (14, 20)

15.5 (12, 20) *a

19.5 (17, 21)

Male

Without Arbidol (n = 24)

With Arbidol (n = 40)

p value

Hospital day [M (IQR)]

19 (14.5, 20)

16 (14, 20)

0.25

Female

Without Arbidol (n = 25)

With Arbidol (n = 32)

p value

Hospital day [M (IQR)]

18 (16.5, 20)

18 (13.3, 21)

0.75

≤ 50 years

Without Arbidol (n = 23)

With Arbidol (n = 49)

p value

Hospital day [M (IQR)]

18 (17, 20)

17 (13.5, 20.5)

0.04*

> 50 years

Without Arbidol (n = 26)

With Arbidol (n = 23)

p value

Hospital day [M (IQR)]

18 (14, 20)

18 (14, 21)

0.94

 ≤ 38.5C

Without Arbidol (n = 33)

With Arbidol (n = 51)

p value

Hospital day [M (IQR)]

19 (16.5, 20)

18 (14, 21)

0.23

> 38.5C

Without Arbidol (n = 16)

With Arbidol (n = 21)

p value

Hospital day [M (IQR)]

17.5 (14, 19)

17 (12.5, 20)

0.73

  1. *Statistically significant p vaues
  2. aControl group versus Arbidol group (p = 0.02)